{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=natalizumab",
    "query": {
      "intervention": "natalizumab"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 82,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=natalizumab&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T04:02:23.307Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04047628",
      "title": "Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing Multiple Sclerosis",
        "Relapsing Remitting Multiple Sclerosis",
        "Secondary Progressive Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Autologous Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Best Available Therapy (BAT)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 156,
      "start_date": "2019-12-19",
      "completion_date": "2029-10",
      "has_results": false,
      "last_update_posted_date": "2026-01-06",
      "last_synced_at": "2026-09-03T04:02:23.307Z",
      "location_count": 22,
      "location_summary": "Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 17 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04047628"
    },
    {
      "nct_id": "NCT00078611",
      "title": "A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "natalizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 462,
      "start_date": "2004-03",
      "completion_date": "2005-03",
      "has_results": false,
      "last_update_posted_date": "2016-06-16",
      "last_synced_at": "2026-09-03T04:02:23.307Z",
      "location_count": 63,
      "location_summary": "Oro Valley, Arizona • Tucson, Arizona • Anaheim, California + 54 more",
      "locations": [
        {
          "city": "Oro Valley",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00078611"
    },
    {
      "nct_id": "NCT03157830",
      "title": "Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Relapsing Remitting Multiple Sclerosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Providence Health & Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 43,
      "start_date": "2017-06-01",
      "completion_date": "2022-06-06",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-09-03T04:02:23.307Z",
      "location_count": 5,
      "location_summary": "Livingston, New Jersey • Portland, Oregon • Richland, Washington + 2 more",
      "locations": [
        {
          "city": "Livingston",
          "state": "New Jersey"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Richland",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03157830"
    },
    {
      "nct_id": "NCT00276172",
      "title": "Open-Label Natalizumab Safety Extension Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Natalizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1615,
      "start_date": "2003-12",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2009-06-22",
      "last_synced_at": "2026-09-03T04:02:23.307Z",
      "location_count": 1,
      "location_summary": "Cambridge, Massachusetts",
      "locations": [
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00276172"
    },
    {
      "nct_id": "NCT01211639",
      "title": "Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Progressive Multifocal Leukoencephalopathy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2010-10",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2015-01-19",
      "last_synced_at": "2026-09-03T04:02:23.307Z",
      "location_count": 10,
      "location_summary": "Cullman, Alabama • Aurora, Colorado • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Hastings",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01211639"
    },
    {
      "nct_id": "NCT00707512",
      "title": "CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "natalizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2008-06-30",
      "completion_date": "2015-05-28",
      "has_results": false,
      "last_update_posted_date": "2024-06-03",
      "last_synced_at": "2026-09-03T04:02:23.307Z",
      "location_count": 35,
      "location_summary": "Scottsdale, Arizona • Oceanside, California • San Francisco, California + 31 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Hamden",
          "state": "Connecticut"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00707512"
    },
    {
      "nct_id": "NCT05172466",
      "title": "Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Relapsing-remitting Multiple Sclerosis (RRMS)"
      ],
      "interventions": [
        {
          "name": "BeCare application",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Icahn School of Medicine at Mount Sinai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 0,
      "start_date": "2022-10-31",
      "completion_date": "2022-11-11",
      "has_results": false,
      "last_update_posted_date": "2022-11-25",
      "last_synced_at": "2026-09-03T04:02:23.307Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05172466"
    },
    {
      "nct_id": "NCT01070836",
      "title": "JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Relapsing Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "natalizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 35895,
      "start_date": "2010-03",
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2016-09-29",
      "last_synced_at": "2026-09-03T04:02:23.307Z",
      "location_count": 473,
      "location_summary": "Birmingham, Alabama • Cullman, Alabama • Tucaloosa, Alabama + 386 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Tucaloosa",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01070836"
    },
    {
      "nct_id": "NCT01860963",
      "title": "Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anal Squamous Intraepithelial Lesion (ASIL)",
        "HPV DNA"
      ],
      "interventions": [
        {
          "name": "Anal Pap smear and HPV DNA testing",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 310,
      "start_date": "2010-01",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2013-10-01",
      "last_synced_at": "2026-09-03T04:02:23.307Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01860963"
    },
    {
      "nct_id": "NCT04837651",
      "title": "Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis",
        "Demyelinating Autoimmune Diseases, CNS",
        "Autoimmune Diseases of the Nervous System",
        "Nervous System Diseases",
        "Demyelinating Diseases",
        "Autoimmune Diseases",
        "Immune System Diseases",
        "Pathologic Processes"
      ],
      "interventions": [
        {
          "name": "Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test",
          "type": "DEVICE"
        },
        {
          "name": "T-Detect COVID T-cell blood test",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Dragonfly Research, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 48,
      "start_date": "2021-03-02",
      "completion_date": "2021-07-01",
      "has_results": false,
      "last_update_posted_date": "2021-08-02",
      "last_synced_at": "2026-09-03T04:02:23.307Z",
      "location_count": 1,
      "location_summary": "Wellesley, Massachusetts",
      "locations": [
        {
          "city": "Wellesley",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04837651"
    }
  ]
}